These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 12372819)

  • 21. The constitutive high-affinity Met-binding site in the kringle domain is dispensable for the signalling activity of hepatocyte growth factor.
    Umitsu M; Sakai K; Tamura-Kawakami K; Matsumoto K; Takagi J
    J Biochem; 2020 Jun; 167(6):577-586. PubMed ID: 31943091
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Functional role of residue 193 (chymotrypsin numbering) in serine proteases: influence of side chain length and beta-branching on the catalytic activity of blood coagulation factor XIa.
    Schmidt AE; Sun MF; Ogawa T; Bajaj SP; Gailani D
    Biochemistry; 2008 Feb; 47(5):1326-35. PubMed ID: 18186617
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of Novel Forms of Coagulation Factor XIa: independence of factor XIa subunits in factor IX activation.
    Smith SB; Verhamme IM; Sun MF; Bock PE; Gailani D
    J Biol Chem; 2008 Mar; 283(11):6696-705. PubMed ID: 18192270
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor.
    Naldini L; Tamagnone L; Vigna E; Sachs M; Hartmann G; Birchmeier W; Daikuhara Y; Tsubouchi H; Blasi F; Comoglio PM
    EMBO J; 1992 Dec; 11(13):4825-33. PubMed ID: 1334458
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A high affinity hepatocyte growth factor-binding site in the immunoglobulin-like region of Met.
    Basilico C; Arnesano A; Galluzzo M; Comoglio PM; Michieli P
    J Biol Chem; 2008 Jul; 283(30):21267-77. PubMed ID: 18495663
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Productive recognition of factor IX by factor XIa exosites requires disulfide linkage between heavy and light chains of factor XIa.
    Marcinkiewicz MM; Sinha D; Walsh PN
    J Biol Chem; 2012 Feb; 287(9):6187-95. PubMed ID: 22207756
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An allosteric switch for pro-HGF/Met signaling using zymogen activator peptides.
    Landgraf KE; Steffek M; Quan C; Tom J; Yu C; Santell L; Maun HR; Eigenbrot C; Lazarus RA
    Nat Chem Biol; 2014 Jul; 10(7):567-73. PubMed ID: 24859116
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activation of hepatocyte growth factor by two homologous proteases, blood-coagulation factor XIIa and hepatocyte growth factor activator.
    Shimomura T; Miyazawa K; Komiyama Y; Hiraoka H; Naka D; Morimoto Y; Kitamura N
    Eur J Biochem; 1995 Apr; 229(1):257-61. PubMed ID: 7744037
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interaction of macrophage-stimulating protein with its receptor. Residues critical for beta chain binding and evidence for independent alpha chain binding.
    Danilkovitch A; Miller M; Leonard EJ
    J Biol Chem; 1999 Oct; 274(42):29937-43. PubMed ID: 10514476
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structure, biosynthesis and biochemical properties of the HGF receptor in normal and malignant cells.
    Comoglio PM
    EXS; 1993; 65():131-65. PubMed ID: 8380735
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular characteristics of HGF-SF and its role in cell motility and invasion.
    Weidner KM; Hartmann G; Naldini L; Comoglio PM; Sachs M; Fonatsch C; Rieder H; Birchmeier W
    EXS; 1993; 65():311-28. PubMed ID: 8380739
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatocyte growth factor and its receptor, the tyrosine kinase encoded by the c-MET proto-oncogene.
    Vigna E; Naldini L; Tamagnone L; Longati P; Bardelli A; Maina F; Ponzetto C; Comoglio PM
    Cell Mol Biol (Noisy-le-grand); 1994 Jul; 40(5):597-604. PubMed ID: 7981617
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structure-function analysis of hepatocyte growth factor: identification of variants that lack mitogenic activity yet retain high affinity receptor binding.
    Lokker NA; Mark MR; Luis EA; Bennett GL; Robbins KA; Baker JB; Godowski PJ
    EMBO J; 1992 Jul; 11(7):2503-10. PubMed ID: 1321034
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Structural basis of hepatocyte growth factor/scatter factor and MET signalling.
    Gherardi E; Sandin S; Petoukhov MV; Finch J; Youles ME; Ofverstedt LG; Miguel RN; Blundell TL; Vande Woude GF; Skoglund U; Svergun DI
    Proc Natl Acad Sci U S A; 2006 Mar; 103(11):4046-51. PubMed ID: 16537482
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The mechanism underlying activation of factor IX by factor XIa.
    Gailani D; Geng Y; Verhamme I; Sun MF; Bajaj SP; Messer A; Emsley J
    Thromb Res; 2014 May; 133 Suppl 1(0 1):S48-51. PubMed ID: 24759143
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Functional characterization of human hepatocyte growth factor mutants obtained by deletion of structural domains.
    Okigaki M; Komada M; Uehara Y; Miyazawa K; Kitamura N
    Biochemistry; 1992 Oct; 31(40):9555-61. PubMed ID: 1327117
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition by copper(II) binding of hepatocyte growth factor (HGF) interaction with its receptor Met and blockade of HGF/Met function.
    Wright TG; Tsai J; Jia Z; Elliott BE
    J Biol Chem; 2004 Jul; 279(31):32499-506. PubMed ID: 15161915
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activation of hepatocyte growth factor by proteolytic conversion of a single chain form to a heterodimer.
    Naka D; Ishii T; Yoshiyama Y; Miyazawa K; Hara H; Hishida T; Kidamura N
    J Biol Chem; 1992 Oct; 267(28):20114-9. PubMed ID: 1328193
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice.
    Kuba K; Matsumoto K; Date K; Shimura H; Tanaka M; Nakamura T
    Cancer Res; 2000 Dec; 60(23):6737-43. PubMed ID: 11118060
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Potent and selective Kunitz domain inhibitors of plasma kallikrein designed by phage display.
    Dennis MS; Herzka A; Lazarus RA
    J Biol Chem; 1995 Oct; 270(43):25411-7. PubMed ID: 7592708
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.